Free Trial
NASDAQ:RGEN

Repligen Q2 2025 Earnings Report

Repligen logo
$127.36 +0.40 (+0.32%)
Closing price 07/3/2025 01:10 PM Eastern
Extended Trading
$127.36 0.00 (0.00%)
As of 07/3/2025 04:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen EPS Results

Actual EPS
N/A
Consensus EPS
$0.40
Beat/Miss
N/A
One Year Ago EPS
N/A

Repligen Revenue Results

Actual Revenue
N/A
Expected Revenue
$174.62 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Repligen Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, July 29, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Repligen Earnings Headlines

Repligen (NASDAQ:RGEN) Downgraded by Wall Street Zen to "Hold"
Elon’s Revenge
Elon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is this: Before he left Washington, Elon Musk left a "parting gift" to folks, which could help you double your money multiple times this year. Everything you need to know is right here.
Repligen (NASDAQ:RGEN) Coverage Initiated at Barclays
See More Repligen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Repligen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Repligen and other key companies, straight to your email.

About Repligen

Repligen (NASDAQ:RGEN) (NASDAQ: RGEN) is a life sciences company specializing in the development and manufacture of bioprocessing technologies for the production of biologic drugs. Founded in 1981 and headquartered in Waltham, Massachusetts, the company provides a suite of consumable products and systems designed to streamline upstream and downstream processes in biomanufacturing. Its offerings include chromatography resins, membrane chromatography devices, single-use filters and sensors, as well as protein A affinity resins utilized in monoclonal antibody purification.

In addition to consumables, Repligen delivers integrated bioprocess systems such as perfusion technologies and cell culture platforms that support continuous processing workflows. The company’s OPUS chromatography columns are engineered for rapid method development and scale-up, while its RUDI perfusion system enables intensified cell culture to increase product yields. These tools are complemented by proprietary single-use assemblies that enhance process efficiency and reduce the risk of cross-contamination.

Repligen serves a global customer base of biopharmaceutical developers and contract manufacturing organizations. With operational facilities and sales offices across North America, Europe, and Asia, the company supports research and commercial manufacturing activities in key biopharma hubs. Its products are widely adopted by leading pharmaceutical companies for applications in antibody, vaccine, gene therapy and cell therapy production.

Under the leadership of President and CEO Dr. Matthew Denton, Repligen has expanded its portfolio through both internal innovation and strategic acquisitions. Guided by a board of directors with extensive experience in biotechnology and pharmaceutical industries, the company continues to invest in research and development to meet the evolving demands of biologics manufacturing. Repligen’s ongoing focus on quality, scale-up support and single-use technologies positions it as a key supplier in the rapidly growing biologics sector.

View Repligen Profile

More Earnings Resources from MarketBeat